AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29311299 — intervention group
Group type: COMPARATOR
Intervention: Neutral coping intervention
Number of subjects: 508
Study 29311299 — intervention group
Group type: COMPARATOR
Intervention: Perspective-taking intervention
Number of subjects: 508
Study 27823683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation (12 weeks physical exercise and four psycho-educational consultations)
Number of subjects: 210
Study 27823683 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 210
Study 27823683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac rehabilitation
Number of subjects: 210
Study 25355680 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant procarbazine, CCNU, and vincristine (PCV) chemotherapy after 54 Gy of radiotherapy (RT)
Number of subjects: 0
Study 25355680 — intervention group
Group type: COMPARATOR
Intervention: 54 Gy of radiotherapy (RT) alone
Number of subjects: 0
Study 23193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianlieping Capsule plus tamsulosin
Number of subjects: 220
Study 23193678 — intervention group
Group type: EXPERIMENTAL
Intervention: Qianlieping Capsule alone
Number of subjects: 220
Study 23193678 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin alone
Number of subjects: 220
Study 20360500 — intervention group
Group type: EXPERIMENTAL
Intervention: Long gamma nail
Number of subjects: 210
Study 20360500 — intervention group
Group type: COMPARATOR
Intervention: Sliding hip screw
Number of subjects: 210
Study 18263885 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious hypnosis
Number of subjects: 30
Study 18263885 — intervention group
Group type: COMPARATOR
Intervention: Verbal motivation by orthodontist (Control)
Number of subjects: 30
Study 18465719 — intervention group
Group type: EXPERIMENTAL
Intervention: Silicone IOL (AQ110NV)
Number of subjects: 339
Study 18465719 — intervention group
Group type: COMPARATOR
Intervention: Rigid PMMA IOL (811C or 824C)
Number of subjects: 339
Study 18465719 — intervention group
Group type: COMPARATOR
Intervention: Acrylic IOL (MA60BM)
Number of subjects: 339
Study 15223898 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose basiliximab with low initial CsA triple therapy (group B)
Number of subjects: 45
Study 15223898 — intervention group
Group type: COMPARATOR
Intervention: Conventional triple therapy (group C)
Number of subjects: 45
Study 15223898 — intervention group
Group type: COMPARATOR
Intervention: Combined analysis of groups B and C
Number of subjects: 45
Study 11725330 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/d for 6 days, then 6 g/d for 4 weeks)
Number of subjects: 16
Study 11725330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9394363 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gemzar)
Number of subjects: 0
Study 8215564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage surfactant regimen (100 mg/kg initially, with two further doses at 12 and 24 hours to a maximum cumulative total of 300 mg/kg; n = 1069)
Number of subjects: 2178
Study 8215564 — intervention group
Group type: COMPARATOR
Intervention: High dosage surfactant regimen (200 mg/kg initially with up to four further doses of 100 mg/kg to a maximum cumulative total of 600 mg/kg; n = 1099)
Number of subjects: 2178
Study 8215564 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage surfactant regimen
Number of subjects: 2178
Study 8215564 — intervention group
Group type: COMPARATOR
Intervention: High dosage surfactant regimen
Number of subjects: 2178
Study 3828659 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral electroconvulsive therapy (ECT)
Number of subjects: 70
Study 3828659 — intervention group
Group type: COMPARATOR
Intervention: Simulated ECT (muscle relaxant and anaesthesia)
Number of subjects: 70
Study 31515428 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrimeprazine 6.25 mg
Number of subjects: 116
Study 31515428 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 1.5 mg
Number of subjects: 116
Study 26975312 — intervention group
Group type: EXPERIMENTAL
Intervention: Transregional interferential current therapy (10 sessions of 25 minutes over two weeks)
Number of subjects: 64
Study 26975312 — intervention group
Group type: COMPARATOR
Intervention: Usual care (massage, mobilization, and soft-tissue techniques)
Number of subjects: 64
Study 26033051 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard infiltration of local anaesthetic
Number of subjects: 75
Study 26033051 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed infiltration of local anaesthetic
Number of subjects: 75
Study 26033051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 24273182 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908-htrA vaccine in H. pylori infected subjects
Number of subjects: 74
Study 24273182 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908-htrA vaccine in subjects with low PG I:PG II ratio (<5)
Number of subjects: 74
Study 24273182 — intervention group
Group type: COMPARATOR
Intervention: CVD 908-htrA vaccine in H. pylori uninfected subjects
Number of subjects: 74
Study 24273182 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD 908-htrA vaccine with Hepatitis A infection
Number of subjects: 74
Study 22938439 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transarterial infusion chemotherapy with gemcitabine (1000 mg/m2) and 5-Fluorouracil (600 mg/m2)
Number of subjects: 48
Study 22938439 — intervention group
Group type: COMPARATOR
Intervention: Systemic venous chemotherapy with gemcitabine (1000 mg/m2) and 5-Fluorouracil (600 mg/m2)
Number of subjects: 48
Study 19692345 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 494
Study 19692345 — intervention group
Group type: COMPARATOR
Intervention: Control (no brief intervention)
Number of subjects: 494
Study 17567623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 3304
Study 17567623 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 3304
Study 15205720 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ALN
Number of subjects: 445
Study 15205720 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ALN
Number of subjects: 445
Study 15205720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 445
Study 15205720 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ALN
Number of subjects: 445
Study 11686821 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine acetate/xylitol gum (ACHX)
Number of subjects: 111
Study 11686821 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol gum (X)
Number of subjects: 111
Study 11686821 — intervention group
Group type: COMPARATOR
Intervention: No gum (N)
Number of subjects: 111
Study 9142362 — intervention group
Group type: EXPERIMENTAL
Intervention: special program
Number of subjects: 125
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis in women with sterility (660 subjects)
Number of subjects: 3684
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis in women with chronic pelvic pain (409 subjects)
Number of subjects: 3684
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis in women with fibroids (1880 subjects)
Number of subjects: 3684
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriosis in women with benign ovarian cysts (735 subjects)
Number of subjects: 3684
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage distribution of endometriosis in women with sterility
Number of subjects: 3684
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage distribution of endometriosis in women with pelvic pain
Number of subjects: 3684
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage distribution of endometriosis in women with fibroids
Number of subjects: 3684
Study 7962393 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage distribution of endometriosis in women with ovarian cysts
Number of subjects: 3684
Study 3305850 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 16
Study 3305850 — intervention group
Group type: COMPARATOR
Intervention: Placebo and diuretics
Number of subjects: 16
Study 3305850 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline and diuretics
Number of subjects: 16
Study 30259166 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 PTS and drains
Number of subjects: 63
Study 30259166 — intervention group
Group type: EXPERIMENTAL
Intervention: 22 PTS and drains
Number of subjects: 63
Study 30259166 — intervention group
Group type: COMPARATOR
Intervention: Classic abdominoplasty without PTS and drains
Number of subjects: 63
Study 26944407 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + probiotic (Lactobacillus rhamnosus SP1), n = 14
Number of subjects: 28
Study 26944407 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo (control), n = 14
Number of subjects: 28
Study 26944407 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + probiotic (Lactobacillus rhamnosus SP1)
Number of subjects: 28
Study 26944407 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo (control)
Number of subjects: 28
Study 24787494 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and low-GI diet (LGI)
Number of subjects: 122
Study 24787494 — intervention group
Group type: COMPARATOR
Intervention: Low-fat and high-GI diet (LF)
Number of subjects: 122
Study 24787494 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and high-GI diet (HGI)
Number of subjects: 122
Study 22673263 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of ubiquitin C-terminal hydrolase (UCH-L1) in TBI patients
Number of subjects: 295
Study 22673263 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of ubiquitin C-terminal hydrolase (UCH-L1) in TBI patients with neurosurgical intervention (NSI)
Number of subjects: 295
Study 22673263 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum levels of ubiquitin C-terminal hydrolase (UCH-L1) in TBI patients with GCS score 15
Number of subjects: 295
Study 20362712 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon catheter
Number of subjects: 244
Study 20362712 — intervention group
Group type: COMPARATOR
Intervention: Open irrigated radiofrequency ablation
Number of subjects: 244
Study 18270772 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic tumor-specific mesorectal excision (R-TSME)
Number of subjects: 36
Study 18270772 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic tumor-specific mesorectal excision (L-TSME)
Number of subjects: 36
Study 15745109 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation (group A; n = 16)
Number of subjects: 31
Study 15745109 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (group B; n = 15)
Number of subjects: 31
Study 15745109 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 31
Study 11785558 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 15
Study 11785558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral with allograft lung down
Number of subjects: 15
Study 11785558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral with native lung down
Number of subjects: 15
Study 10598223 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous suture (group T)
Number of subjects: 100
Study 10598223 — intervention group
Group type: COMPARATOR
Intervention: Manual compression (group C)
Number of subjects: 100
Study 7750282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone subdermal implant (Implant A)
Number of subjects: 70
Study 7750282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone subdermal implant (Implant B)
Number of subjects: 70
Study 7750282 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone subdermal implant
Number of subjects: 70
Study 7750282 — intervention group
Group type: COMPARATOR
Intervention: Copper T users (Control)
Number of subjects: 70
Study 2301245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 0
Study 2301245 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 7350294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 6
Study 7350294 — intervention group
Group type: EXPERIMENTAL
Intervention: Human growth hormone (hGH)
Number of subjects: 6
Study 7350294 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone + Human growth hormone (Ox + hGH)
Number of subjects: 6
Study 7350294 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 6
Study 31528866 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafted sinuses
Number of subjects: 12
Study 31528866 — intervention group
Group type: COMPARATOR
Intervention: Nongrafted sinuses
Number of subjects: 12
Study 28638060 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural group (Group E): TEA with levobupivacaine and dexmedetomidine, intravenous saline infusion
Number of subjects: 71
Study 28638060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous group (Group V): TEA with levobupivacaine, intravenous dexmedetomidine infusion
Number of subjects: 71
Study 28638060 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C): TEA with levobupivacaine alone, intravenous saline infusion
Number of subjects: 71
Study 25854859 — intervention group
Group type: COMPARATOR
Intervention: Pradigastat (1, 3, 10, 30, 100, or 300 mg)
Number of subjects: 178
Study 25854859 — intervention group
Group type: COMPARATOR
Intervention: Pradigastat (1, 5, 10, or 25 mg)
Number of subjects: 178
Study 25854859 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat (single and multiple doses)
Number of subjects: 178
Study 24088535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) Intervention I (weekly group sessions + self‐instructing program)
Number of subjects: 0
Study 24088535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR) Intervention II (self‐instructing program)
Number of subjects: 0
Study 24088535 — intervention group
Group type: COMPARATOR
Intervention: Controls (non‐MBSR)
Number of subjects: 0
Study 21843685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg orally and misoprostol 800 mcg vaginally
Number of subjects: 27
Study 21843685 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg
Number of subjects: 27
Study 19121595 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resolution Fd-OCT imaging
Number of subjects: 30
Study 17920976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl (INF) 180 mug +/‐ 2 doses of 60 mug at > or =5‐minute intervals
Number of subjects: 258
Study 17920976 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (IVM) 2.5 to 5 mg +/‐ 2 doses of 2.5 to 5 mg at > or =5‐minute intervals
Number of subjects: 258
Study 17920976 — intervention group
Group type: COMPARATOR
Intervention: Baseline VRS
Number of subjects: 258
Study 17920976 — intervention group
Group type: COMPARATOR
Intervention: Minutes to destination
Number of subjects: 258
Study 17920976 — intervention group
Group type: COMPARATOR
Intervention: Higher baseline VRS
Number of subjects: 258
Study 17920976 — intervention group
Group type: COMPARATOR
Intervention: No methoxyflurane use
Number of subjects: 258
Study 17920976 — intervention group
Group type: COMPARATOR
Intervention: Back pain
Number of subjects: 258
Study 17920976 — intervention group
Group type: COMPARATOR
Intervention: Safety and acceptability
Number of subjects: 258
Study 15257846 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider counseling, health education, and CHW support
Number of subjects: 217
Study 15257846 — intervention group
Group type: COMPARATOR
Intervention: Provider counseling
Number of subjects: 217
Study 15257846 — intervention group
Group type: COMPARATOR
Intervention: Provider counseling and health education
Number of subjects: 217
Study 11239945 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa (on state)
Number of subjects: 20
Study 11239945 — intervention group
Group type: COMPARATOR
Intervention: levodopa (off state)
Number of subjects: 20
Study 11239945 — intervention group
Group type: EXPERIMENTAL
Intervention: verbal working memory measure (on and off states)
Number of subjects: 20
Study 11239945 — intervention group
Group type: EXPERIMENTAL
Intervention: verbal working memory measure (on state)
Number of subjects: 20
Study 9659015 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (n = 25)
Number of subjects: 51
Study 9659015 — intervention group
Group type: COMPARATOR
Intervention: Halothane (n = 26)
Number of subjects: 51
Study 8698737 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexverapamil plus chemotherapy (vindesine/etoposide)
Number of subjects: 54
Study 8698737 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (vindesine/etoposide) alone
Number of subjects: 54
Study 2549243 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre, low fat and low sodium diet
Number of subjects: 34
Study 2549243 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 34
Study 302111 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of vasopressin via peripheral vein
Number of subjects: 25
Study 302111 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of vasopressin via superior mesenteric artery (SMA)
Number of subjects: 25
Study 30773030 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT) for 9 months (4×4-minute intervals at 85%-95% of peak effort)
Number of subjects: 81
Study 30773030 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training for 9 months (60%-80% of peak effort)
Number of subjects: 81
Study 29627898 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRI treatment with paroxetine for 8 weeks
Number of subjects: 178
Study 27028170 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy (IMRT)
Number of subjects: 215
Study 27028170 — intervention group
Group type: COMPARATOR
Intervention: 3-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 215
Study 25450993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 18
Study 25450993 — intervention group
Group type: COMPARATOR
Intervention: Muscle Training (CT)
Number of subjects: 18
Study 25450993 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AT and CT
Number of subjects: 18
Study 22455636 — intervention group
Group type: COMPARATOR
Intervention: PaO2 levels controlled at 80 ‐ 120 mm Hg during CPB (G1 group)
Number of subjects: 45
Study 22455636 — intervention group
Group type: COMPARATOR
Intervention: PaO2 levels controlled at 120 ‐ 200 mm Hg during CPB (G2 group)
Number of subjects: 45
Study 22455636 — intervention group
Group type: EXPERIMENTAL
Intervention: PaO2 levels uncontrolled at 200 ‐ 400 mm Hg during CPB (G3 group)
Number of subjects: 45
Study 20008967 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking of others with good trait or state self-control
Number of subjects: 0
Study 20008967 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking of others with bad trait or state self-control
Number of subjects: 0
Study 20008967 — intervention group
Group type: EXPERIMENTAL
Intervention: Salience of significant others
Number of subjects: 0
Study 19230167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin
Number of subjects: 20
Study 19230167 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 20
Study 16141019 — intervention group
Group type: EXPERIMENTAL
Intervention: Human patient simulator (SIM)
Number of subjects: 36
Study 16141019 — intervention group
Group type: COMPARATOR
Intervention: Human subjects in the operating room (OR)
Number of subjects: 36
Study 12884163 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin therapy
Number of subjects: 165
Study 12884163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 10576371 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 (120 microg/day for 5 days)
Number of subjects: 20
Study 10576371 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 8726538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal apomorphine monotherapy
Number of subjects: 11
Study 8726538 — intervention group
Group type: COMPARATOR
Intervention: Levodopa/carbidopa
Number of subjects: 11
Study 8726538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal apomorphine
Number of subjects: 11
Study 8726538 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal apomorphine with trimethobenzamide
Number of subjects: 11
Study 1756271 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan (L-PAM)
Number of subjects: 158
Study 1756271 — intervention group
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 158
Study 1756271 — intervention group
Group type: EXPERIMENTAL
Intervention: post-operative radiation therapy (RT)
Number of subjects: 158
Study 1756271 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy alone
Number of subjects: 158
Study 1756271 — intervention group
Group type: EXPERIMENTAL
Intervention: less than 4 positive nodes
Number of subjects: 158
Study 1756271 — intervention group
Group type: EXPERIMENTAL
Intervention: greater than or equal to 4 positive nodes
Number of subjects: 158
Study 7169959 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol diether (promestriene) administered via gynaecological capsules for 40 consecutive days
Number of subjects: 38
Study 7169959 — intervention group
Group type: COMPARATOR
Intervention: Excipient (control) administered via gynaecological capsules for 40 consecutive days
Number of subjects: 38
Study 6368883 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 14
Study 6368883 — intervention group
Group type: COMPARATOR
Intervention: Clofibrate
Number of subjects: 14
Study 30471141 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) with APAP
Number of subjects: 24
Study 30471141 — intervention group
Group type: COMPARATOR
Intervention: Placebo with APAP
Number of subjects: 24
Study 29320335 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (physician training with communication guide and in-office sessions)
Number of subjects: 479
Study 29320335 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 479